Literature DB >> 15280181

Genetic alterations in hereditary breast cancer.

G Cipollini1, S Tommasi, A Paradiso, P Aretini, F Bonatti, I Brunetti, M Bruno, G Lombardi, F Schittulli, E Sensi, M Tancredi, G Bevilacqua, M A Caligo.   

Abstract

Genetic linkage studies have led to the identification of highly penetrant genes as the possible cause of inherited cancer risk in many cancer-prone families. Most women with a family history of breast/ovarian cancer have tumors characterized by alterations in particular genes, mainly BRCA1 and BRCA2, but also CHK2, ATM, STK11 and others. This paper examines the BRCA1 and BRCA2 genes, focusing on the Italian pattern of mutations. The function of these two genes, classified as tumor suppressors, is linked with key metabolic mechanisms such as DNA damage repair, regulation of gene expression and cell cycle control. The pathological BRCA allelic variants may cause alteration of protein function, transcriptional activity and DNA repair; accumulation of the defects leads to widespread chromosome instability that may be directly responsible for cancer formation. In fact, mutations in BRCA1 and BRCA2, conferring a highly increased susceptibility to breast and ovarian cancer, do not lead to cancer by themselves. The current consensus is that these are 'caretaker' genes, which, when inactivated, allow other genetic defects to accumulate. The nature of these other molecular events may define the pathway through which BRCA1 and BRCA2 act. The BRCA mutation spectrum is complex, and the significance of most nucleotide alterations is difficult to understand. Moreover, the mutation pattern seems to be related to ethnicity. The Italian Consortium of Hereditary Breast and Ovarian Cancer has reviewed 1758 families; 23% have been found to be carriers of pathogenetic mutations in BRCA1 or BRCA2. Founder mutations have been described in geographically restricted areas of Italy; a regional founder effect has been demonstrated in Italy for the mutations BRCA1 5083del19 and BRCA2 8765delAG, and a probable new founder mutation has been characterized in Tuscany. The presence of founder mutations has practical implications for genetic testing. Copyright 2004 European Society for Medical Oncology

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15280181     DOI: 10.1093/annonc/mdh651

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  12 in total

Review 1.  Impact of germline and somatic BRCA1/2 mutations: tumor spectrum and detection platforms.

Authors:  H Wu; X Wu; Z Liang
Journal:  Gene Ther       Date:  2017-08-03       Impact factor: 5.250

2.  Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer.

Authors:  Ivana Antonucci; Martina Provenzano; Luca Sorino; Michela Balsamo; Gitana Maria Aceto; Pasquale Battista; David Euhus; Ettore Cianchetti; Patrizia Ballerini; Clara Natoli; Giandomenico Palka; Liborio Stuppia
Journal:  J Hum Genet       Date:  2016-12-08       Impact factor: 3.172

Review 3.  Molecular screening for breast cancer prevention, early detection, and treatment planning: combining biomarkers from DNA, RNA, and protein.

Authors:  Katherine Stemke-Hale; Bryan Hennessy; Gordon B Mills; Rahul Mitra
Journal:  Curr Oncol Rep       Date:  2006-11       Impact factor: 5.075

4.  Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition.

Authors:  Andreas Höglund; Kerstin Strömvall; Yongmei Li; Linus Plym Forshell; Jonas A Nilsson
Journal:  Cell Cycle       Date:  2011-10-15       Impact factor: 4.534

5.  Identification of novel candidate genes by exome sequencing in Tunisian familial male breast cancer patients.

Authors:  Wala Ben Kridis-Rejeb; Dorra Ben Ayed-Guerfali; Nihel Ammous-Boukhris; Wajdi Ayadi; Chamseddine Kifagi; Slim Charfi; Ines Saguem; Tahia Sellami-Boudawara; Jamel Daoud; Afef Khanfir; Raja Mokdad-Gargouri
Journal:  Mol Biol Rep       Date:  2020-09-08       Impact factor: 2.316

6.  Mitochondria and familial predisposition to breast cancer.

Authors:  Stefania Weigl; Angelo Paradiso; Stefania Tommasi
Journal:  Curr Genomics       Date:  2013-05       Impact factor: 2.236

7.  Relationship between family history of breast cancer and clinicopathological features in Moroccan patients.

Authors:  Amal Tazzite; Hassan Jouhadi; Kamal Saiss; Abdellatif Benider; Sellama Nadifi
Journal:  Ethiop J Health Sci       Date:  2013-07

8.  Family history in breast cancer in São Luís, Maranhão, Brazil.

Authors:  Maria Hilda Araújo Ribeiro; Marcos Antonio Custódio Neto da Silva; Walbert Edson Muniz Filho; Anna Cyntia Brandão Nascimento; Rodrigo Duart Martins Souza; Carlos Eduardo Everton Machado; Dulcelena Ferreira Silva; Geusa Felipa de Barros Bezerra; Graça Maria de Castro Viana; Maria do Desterro Soares Brandão Nascimento
Journal:  BMC Res Notes       Date:  2016-03-10

Review 9.  Effects of the lifestyle habits in breast cancer transcriptional regulation.

Authors:  Marco Allán Pérez-Solis; Guadalupe Maya-Nuñez; Patricia Casas-González; Aleida Olivares; Arturo Aguilar-Rojas
Journal:  Cancer Cell Int       Date:  2016-02-13       Impact factor: 5.722

10.  A role of BRCA1 and BRCA2 germline mutations in breast cancer susceptibility within Sardinian population.

Authors:  Grazia Palomba; Angela Loi; Antonella Uras; Patrizia Fancello; Giovanna Piras; Attilio Gabbas; Antonio Cossu; Mario Budroni; Antonio Contu; Francesco Tanda; Antonio Farris; Sandra Orrù; Carlo Floris; Marina Pisano; Mario Lovicu; Maria Cristina Santona; Gennaro Landriscina; Laura Crisponi; Giuseppe Palmieri; Maria Monne
Journal:  BMC Cancer       Date:  2009-07-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.